TORONTO, ON--(NewMediaWire - Dec 14, 2016) - Easton
Pharmaceuticals, Inc. (OTC PINK: EAPH) is pleased to announce that its partner
BMV Medica SA de C.V. through its host company Ackerman Pharma, has
signed a Sales & Marketing Agreement with Gedeon Richter Mexico
S.A.P.I. de C.V. a Mexican-based company and affiliate of Gedeon
Richter Plc, for Easton / BMV's "Gynofit" Lactic Acid Gel for the
treatment of Bacterial Vaginosis in Mexico. http://www.richter.hu/en-US/Pages/default.aspx
The sales and marketing agreement is for the country of Mexico,
a pharmaceutical market representing almost 40% of Latin America,
possessing double-digit annual growth rates. Marketing and Sales of
"Gynofit" are expected to commence In February of 2017. "This
Agreement is instrumental for Easton / BMV's Latin American growth
plans." Mr. Evan Karras, CEO of Easton Pharmaceuticals stated. Mr.
Karras further commented, "This represents a strong strategic
relationship for Easton / BMV as Gedeon Richter Plc and its
affiliate company, Mexico S.A.P.I de C.V. is a premier
international pharmaceutical company focused on Women's Health,
with a presence in more than 38 countries with 5 manufacturing
facilities, 29 representative offices, 38 commercial subsidiaries
and wholesale companies employing approximately 1000 people. This
agreement adds to our previous distribution agreement announcement
for Central America and the Dominican Republic for our exclusive
Women's Heath line of products. We will continue to increase our
distribution channels and sales opportunities in other territories
for Gynofit and our patented, licensed and exclusive VagiSan
(VS-Sense) and AmnioSense (AL-Sense) line of products."
"Gynofit" is a natural product treatment for women who are
diagnosed with BV (Bacterial Vaginosis), a condition that affects
nearly all women at some point in their lives and is one of the
most common reasons for gynecological visits by women. In addition,
Gynofit will be promoted for help in maintenance of a healthy
vaginal flora. The agreement with Gedeon Richter Mexico S.A.P.I de
C.V. provides for setting annual minimums in return for granting
exclusivity. Gedeon Richter Plc and Gedeon Richter Mexico S.A.P.I.
de C.V. has committed to a strong marketing support for Gynofit,
which Easton believes will steadily drive sales in Mexico over the
next three years and beyond.
The agreement with Gedeon Richter Mexico S.A.P.I . de C.V. for
"Gynofit" is separate from Easton / BMV's other patented and
exclusive diagnostic products (VagiSan (VS-Sense) & AmnioSense
(AL-Sense) for which Easton is currently in separate late stage
negotiations with large multi-national pharmaceutical
companies.
In other developments, Easton Pharmaceuticals has entered into
and are in late stage negotiations with BMV Medica SA de C.V. to
acquire all of BMV and its assets. In addition, Easton is in late
stage negotiations for an international medical marijuana
initiative and to acquire a profitable and steadily growing
Vaporizer company with their own line of manufactured and
proprietary e-liquids and accessories, possessing growing
international sales. News updates to be made available as they
develop.
For More Detailed Information on Gedeon Richter Plc
Visit:
http://www.richter.hu/en-US/Pages/default.aspx
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical
company involved in various pharmaceutical sectors and other
growing industries. The Company previously developed and owned an
FDA-approved wound-healing drug and currently owns topically
delivered drugs to treat cancer and other therapeutic products to
treat various conditions that are all in various stages of
development and approval. Easton has partnered with BMV Medica SA
de C.V. and together, own the exclusive distribution rights in
Mexico and Latin America for patented women's diagnostic and
preventative care products from CommonSense Of Israel, along with
two generic cancer drugs, Paclitaxel and Docetaxel from BioLyse
Pharma of St. Catherine's Ontario, Canada.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://www.bmvmedica.net
http://ecigmarkets.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or
expressions within the meaning of the Private Securities Litigation
Reform Act of 1995 (The "Act"). In particular, when certain words
or phrases such as "hope," "positive," "anticipate," "pleased,"
"plan," "confident that," "believe," "expect," "possible" or
"intent to" and similar conditional expressions are expressed, they
are intended to identify forward-looking statements within the
meaning of the Act and are subject to the safe harbor created by
the Act. Such statements are subject to certain risks and
uncertainties and actual results could differ materially from those
expressed in any of the forward-looking statements. Any risks and
uncertainties include, but are not limited to, market conditions,
general acceptance of the company's products and technologies,
competitive factors, the ability to successfully complete
additional or adequate financing, government approvals or changes
to proposed laws and other risks and uncertainties further stated
in the company's financial reports and filings.